ClinicalTrials.Veeva

Menu

Dose-staged Gamma Knife Radiosurgery Versus Microsurgical Resection

Medical University of Vienna logo

Medical University of Vienna

Status

Enrolling

Conditions

Brain Metastases

Treatments

Procedure: Microsurgical resection
Procedure: Gamma Knife radiosurgery

Study type

Interventional

Funder types

Other

Identifiers

NCT04857905
EK 1623/2020

Details and patient eligibility

About

Background. Brain metastases (BM) are the most common intracranial tumor and occur in 20-40% of all oncological patients. The most common primary cancer in brain metastases is lung cancer, followed by melanoma, breast cancer, renal cancer and colorectal cancer. The incidence of brain metastases has been increasing but the occurrence of brain metastases is still associated with high morbidity and poor prognosis. The main treatment methods are stereotactic radiosurgery (SRS), microsurgical resection and whole brain irradiation (WBRT). In contrast to microsurgical resection, Gamma Knife radiosurgery (GKRS) is a non-invasive neurosurgical method, which allows treatment in multimorbid patients with contraindications for surgery in general anesthesia. Furthermore, stereotactic radiosurgery is the only local treatment method for multiple disseminated and thereby non-resectable brain metastases. In general, microsurgical resection is considered the treatment of choice for BM exceeding >3 cm in diameter. However, since the establishment of the dose-staged technique, larger metastases can also be treated radiosurgically in selected patients. This novel method allows the application of high cumulative dose for the treatment of complex brain metastases.

Aim. The aim of the study is to evaluate the clinical outcome in brain metastases patients with tumor volume between 8 and 20 ccm3. The clinical outcome will be compared between surgically and radiosurgically treated BM patients.

Patients and methods. The investigators plan to conduct an explorative prospective study including about 50 radiosurgically and 50 surgically treated patients with brain metastases. If a patient fulfill study-relevant inclusion criteria at the time of BM diagnosis, the principle study investigator will offer both treatment options to the patient. Depending on patient's choice, he/she will be categorized either to surgical or to radiosurgical treatment group. For the outcome evaluation of the different treatment options, a comprehensive database will be established. The study participations will not interfere with any clincally indicated therapeutic decisions and the study participants will not be exposed to any additional risks since both treatments represent suitable therapy options.

Enrollment

100 estimated patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients over 18 years and under 90 years
  • Patients with KPS ≥70
  • Patients with NSCLC, melanoma, breast cancer or renal cancer as primary tumor
  • Maximum of three brain metastases on the diagnostic MRI
  • Tumor volume of 8-20 ccm3 on the diagnostic MRI
  • Lobular brain metastases
  • Patients without any contraindications for both treatment options
  • Written, signed informed consent for study particaption after study explanation

Exclusion criteria

  • Patients under 18 years and over 90 years
  • Patients with KPS <70
  • Patients with other primary tumor
  • More than three brain metastases on the diagnostic MRI
  • Tumor volume <8 or >20 ccm3 on the diagnostic MRI
  • Patients with contraindications for both treatment options

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

100 participants in 2 patient groups

Microsurgical Resection of larger Brain Metastasis
Other group
Description:
Patients over 18 years and under 90 years Patients with KPS ≥70 Patients with NSCLC, melanoma, breast cancer or renal cancer as primary tumor Maximum of three brain metastases on the diagnostic MRI Tumor volume of 8-20 ccm3 on the diagnostic MRI Lobular brain metastases Patients without any contraindications for both treatment options Written, signed informed consent for study particaption after counseling -\> Patients who after counseling decide for microsurgical resection of their brain metastasis
Treatment:
Procedure: Microsurgical resection
Radiosurgery of larger Brain Metastasis
Other group
Description:
Patients over 18 years and under 90 years Patients with KPS ≥70 Patients with NSCLC, melanoma, breast cancer or renal cancer as primary tumor Maximum of three brain metastases on the diagnostic MRI Tumor volume of 8-20 ccm3 on the diagnostic MRI Lobular brain metastases Patients without any contraindications for both treatment options Written, signed informed consent for study particaption after study counseling -\> Patients who after counseling decide for dose-staged radiosurgical treatment of their brain metastasis
Treatment:
Procedure: Gamma Knife radiosurgery

Trial contacts and locations

1

Loading...

Central trial contact

Josa Frischer, MD, PhD; Anna Cho, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems